Interstitial Cystitis Association

The Interstitial Cystitis Association (ICA) is a national nonprofit organization offering information and support to patients with IC and their families, educating the medical community about IC, and promoting research to find effective treatments for IC.

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

As part of the National Institutes of Health, the NIDDK develops, reviews, and distributes publications. The NIDDK works closely with professional and patient organizations and government agencies to relay information about IC.

Patients can find helpful information on the diagnosis and treatment of IC, research updates on clinical studies, suggested reading ideas, and more.

IMPORTANT SAFETY INFORMATION

Contraindications: ELMIRON^® is contraindicated in patients with known hypersensitivity to the drug, structurally related compounds, or excipients.
Anticoagulant Activity: ELMIRON^® is a weak anticoagulant (blood thinner) which may increase bleeding. Patients undergoing invasive surgery or having signs/symptoms of underlying coagulopathy or other increased risk of bleeding (due to anticoagulant therapy or high doses of anti-inflammatory drugs) should be evaluated for the risk of hemorrhage.
Alopecia: In clinical trials of ELMIRON^®, alopecia began within the first 4 weeks of treatment. Ninety-seven percent (97%) of the cases of alopecia reported were alopecia areata, limited to a single area on the scalp.
Use in Pregnancy: ELMIRON^® is a Pregnancy Category B drug.
Most Common Adverse Reactions (frequency 1% to 4%): Alopecia (4%), diarrhea (4%), nausea (4%), headache (3%), rash (3%), dyspepsia (2%), abdominal pain (2%), liver function abnormalities (1%), and dizziness (1%).

Please see full Prescribing Information for ELMIRON^®.

02E10016P

Additional Resources

Interstitial Cystitis Association

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)